TABLE 4.
Multivariable-adjusted ORs (95% CIs) of dropouts at 12 mo during a commercial weight-loss program including a VLCD (500 kcal/d) or an LCD (1200–1500 kcal/d)1
| VLCD (n = 532 dropouts) |
LCD (n = 818 dropouts) |
|||
| OR (95% CI) | P | OR (95% CI) | P | |
| Male sex | 0.84 (0.65, 1.09) | 0.18 | 0.97 (0.76, 1.24) | 0.81 |
| Age | ||||
| ≥60 y | Reference | Reference | ||
| 50–59 y | 1.13 (0.71, 1.81) | 0.61 | 1.24 (0.97, 1.59) | 0.092 |
| 40–49 y | 2.47 (1.57, 3.90) | <0.001 | 1.67 (1.28, 2.17) | <0.001 |
| <40 y | 4.12 (2.61, 6.50) | <0.001 | 2.68 (2.04, 3.51) | <0.001 |
| P-trend | <0.001 | <0.001 | ||
| Baseline BMI | ||||
| ≥40 kg/m2 | Reference | Reference | ||
| 35–39 kg/m2 | 1.17 (0.81, 1.68) | 0.42 | 2.58 (1.29, 5.15) | 0.007 |
| 30–34 kg/m2 | 1.46 (1.04, 2.05) | 0.027 | 2.50 (1.29, 4.84) | 0.007 |
| <30 kg/m2 | 1.35 (0.92, 1.98) | 0.13 | 3.02 (1.57, 5.81) | 0.001 |
| P-trend | 0.082 | 0.003 | ||
| Weight loss at 3 mo | ||||
| ≥15% | Reference | Reference | ||
| 10–14% | 1.50 (1.19, 1.88) | 0.001 | 1.39 (0.92, 2.11) | 0.12 |
| 5–9% | 2.49 (1.91, 3.24) | <0.001 | 2.51 (1.67, 3.76) | <0.001 |
| <5% | 3.41 (2.33, 5.00) | <0.001 | 4.99 (3.27, 7.63) | <0.001 |
| P-trend | <0.001 | <0.001 | ||
| Comorbidities and drug use | ||||
| History of cancer | 1.24 (0.57, 2.73) | 0.59 | 0.98 (0.58, 1.64) | 0.98 |
| History of CVD | 1.04 (0.70, 1.55) | 0.82 | 1.09 (0.80, 1.48) | 0.60 |
| Antihypertension drugs | 1.00 (0.71, 1.42) | 1.00 | 1.09 (0.85, 1.38) | 0.50 |
| Antidyslipidemia drugs | 0.88 (0.51, 1.55) | 0.66 | 0.89 (0.63, 1.25) | 0.63 |
| Antidiabetes drugs | 1.31 (0.62, 2.74) | 0.48 | 0.92 (0.52, 1.62) | 0.76 |
| Antidepression drugs | 1.44 (1.08, 1.91) | 0.013 | 1.24 (0.99, 1.55) | 0.065 |
| Antipsychosis drugs | 2.63 (1.09, 6.32) | 0.031 | 0.55 (0.23, 1.33) | 0.18 |
| Antiobesity drugs | 0.73 (0.32, 1.67) | 0.49 | 1.25 (0.55, 2.84) | 0.60 |
Drug use was assessed during the period 6 mo before baseline through register linkage with the Prescribed Drug Register, whereas comorbidity data (except for diabetes) were retrieved from the National Patient Register during the past 5 y. Because diabetes is, to a large extent, treated in primary care, it was defined as use of either insulin or oral antidiabetics. We were not able to analyze the restricted normal-food diet group because of insufficient power and likewise for the antiobesity drug orlistat (only sibutramine was analyzed). There were 3466 participants with complete data on dropout predictors in the VLCD group (91.9%), of whom 532 dropped out, and 4163 in the LCD group (90.7%), of whom 818 dropped out. ORs were quantified by using multivariable logistic regression. CVD, cardiovascular disease; LCD, low-calorie diet; VLCD, very-low-calorie diet.